Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 43-47

  Curtis, J R ^a   Beukelman, T ^a   Onofrei, A ^b   Cassell, S ^c   Greenberg, J D ^d   Kavanaugh, A ^e   Reed, G ^b   Strand, V ^f   Kremer, J M ^g  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Los Alamos Oversight Bureau   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f STANFORD UNIVERSITY   (United States)

^g ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD COMPLEX; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; MINOCYCLINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT MONITORING; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CLINICAL ENZYME TESTS; COHORT STUDIES; DRUG MONITORING; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; YOUNG ADULT;

EID: 73449096104     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.101378     Document Type: Article

References (16)

1. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44:1984-92.
2. Kremer JM, Kaye GI, Kaye NW, et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995;38:1194-203.
3. Kremer JM, Furst DE, Weinblatt ME, et al. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996;23:459-61.
4. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
5. Kremer JM, Galivan J, Streckfuss A, et al. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-5.
6. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989;32:121-7.
7. Kent PD, Luthra HS, Michet C Jr. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol 2004;31:1727-31.
8. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6.
9. Kremer JM. The CORRONA database. Autoimmun Rev 2006;5:46-54.
10. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65.
11. Kremer J, Genovese M, Cannon GW, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004;31:1521- 31.
12. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
13. Lazo M, Selvin E, Clark JM. Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 2008;148:348-52.
14. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
15. Wollina U, Stander K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis-short- and long-term toxicity in 104 patients. Clin Rheumatol 2001;20:406-10.
16. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.